NASDAQ:ACET Adicet Bio Q3 2025 Earnings Results & Report $2.99 -0.01 (-0.33%) Closing price 04:00 PM EasternExtended Trading$3.12 +0.13 (+4.31%) As of 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Adicet Bio missed analyst earnings expectations in its Q3 2025 results, released November 5, 2025. The company reported EPS of -$4.64 versus the -$4.16 consensus estimate. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ3 2025Report DateNovember 5, 2025TimeBefore Market OpensConference Call7:00 AM ET Adicet Bio EPS ResultsActual EPS-$4.64Consensus EPS -$4.16Beat/MissMissed by -$0.48One Year Ago EPSN/AEPS Beat Rate4 of last 8 quartersAdicet Bio Revenue ResultsActual RevenueN/AExpected Revenue$2.50 millionBeat/MissN/AYoY Revenue GrowthN/AConference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsEarnings Release(8-K)Quarterly Report(10-Q) Adicet Bio Q3 2025 Earnings FAQ Did Adicet Bio beat earnings estimates for Q3 2025? Adicet Bio (NASDAQ:ACET) reported earnings of -$4.64 per share for Q3 2025, missing the consensus estimate of -$4.16. The report was announced on Wednesday, November 5, 2025. Adicet Bio Earnings HeadlinesAdicet Bio (ACET) Stock Fair Value Moves Lower After Prula Cel Lupus DataNovember 11 at 4:25 AM | finance.yahoo.comAdicet Bio (ACET) Projected to Announce Quarterly Earnings on WednesdayNovember 3, 2026 | americanbankingnews.comYour free book is about to disappearBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time through a temporary download link. He plans to charge for it soon. Download your copy now and lock it in at no cost, regardless of future pricing.November 11 at 1:00 AM | Profits Run (Ad)Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)October 30, 2026 | businesswire.comAnalysts Offer Insights on Healthcare Companies: IQVIA Holdings (IQV) and Adicet Bio (ACET)September 30, 2026 | theglobeandmail.comAdicet Bio reports positive Prula-cel phase 1 lupus data as pivotal study plans advanceSeptember 28, 2026 | msn.comSee More Adicet Bio Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Adicet Bio? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Adicet Bio and other key companies, straight to your email. Email Address About Adicet BioAdicet Bio (NASDAQ:ACET) is a clinical-stage biotechnology company developing allogeneic T-cell therapies for the treatment of cancer. The company’s platform is focused on genetically engineered gamma delta T cells, an immune-cell type that can recognize and attack abnormal cells while potentially offering advantages for off-the-shelf cell therapy development. Adicet’s product candidates are designed to incorporate chimeric antigen receptors and other modifications intended to improve tumor targeting, persistence, and activity. Its lead programs have included ADI-001, an investigational allogeneic gamma delta CAR T-cell therapy targeting CD19 for certain B-cell malignancies, including relapsed or refractory large B-cell lymphoma. The company has also pursued additional candidates aimed at hematologic cancers and solid tumors. Founded in 2014 and headquartered in Redwood City, California, Adicet Bio has advanced its programs through collaborations and clinical development activities in the United States and internationally. The company is led by Chief Executive Officer Chen Schor. Its therapies remain investigational and are subject to clinical testing and regulatory review.View Adicet Bio ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Keeping AI Cool: AAON Rides the AI Heatwave to Record GrowthCan Constellation Energy's Contracts Power a Stock Rebound?IonQ Raised the Bar, But 3 Quantum Rivals Face Tough QuestionsAmazon's Rally Is Outpacing Big Tech, But Can AWS Justify the AI Spending?Aehr Test Systems Notches Another Post-Earnings Win as Sales Triple on AI DemandAST SpaceMobile Has a New Rocket Plan, But Its Cash-Burn Problem Isn't Going AwayPowering Up the Moon: Redwire’s $40 Million NASA Award Upcoming Earnings Brookfield (11/12/2026)NU (11/12/2026)Applied Materials (11/12/2026)Cisco Systems (11/12/2026)Mizuho Financial Group (11/13/2026)Mitsubishi UFJ Financial Group (11/13/2026)Sumitomo Mitsui Financial Group (11/13/2026)Home Depot (11/17/2026)Walt Disney (11/17/2026)NVIDIA (11/17/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
